- Home
- RDW vs DNTH Comparison
RDW vs DNTH Comparison
Compare RDW & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDW
- DNTH
- Stock Information
- Founded
- RDW 2020
- DNTH 2015
- Country
- RDW United States
- DNTH United States
- Employees
- RDW N/A
- DNTH N/A
- Industry
- RDW Military/Government/Technical
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- RDW Industrials
- DNTH Health Care
- Exchange
- RDW Nasdaq
- DNTH Nasdaq
- Market Cap
- RDW 800.5M
- DNTH 711.2M
- IPO Year
- RDW N/A
- DNTH N/A
- Fundamental
- Price
- RDW $13.93
- DNTH $23.80
- Analyst Decision
- RDW Strong Buy
- DNTH Strong Buy
- Analyst Count
- RDW 5
- DNTH 9
- Target Price
- RDW $10.95
- DNTH $46.43
- AVG Volume (30 Days)
- RDW 878.1K
- DNTH 203.7K
- Earning Date
- RDW 11-06-2024
- DNTH 11-07-2024
- Dividend Yield
- RDW N/A
- DNTH N/A
- EPS Growth
- RDW N/A
- DNTH N/A
- EPS
- RDW N/A
- DNTH N/A
- Revenue
- RDW $298,026,000.00
- DNTH $5,366,000.00
- Revenue This Year
- RDW $28.47
- DNTH $98.73
- Revenue Next Year
- RDW $18.23
- DNTH N/A
- P/E Ratio
- RDW N/A
- DNTH N/A
- Revenue Growth
- RDW 27.35
- DNTH 51.41
- 52 Week Low
- RDW $2.68
- DNTH $8.24
- 52 Week High
- RDW $15.25
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- RDW 61.81
- DNTH 46.14
- Support Level
- RDW $12.27
- DNTH $22.59
- Resistance Level
- RDW $14.09
- DNTH $24.57
- Average True Range (ATR)
- RDW 1.25
- DNTH 1.49
- MACD
- RDW -0.09
- DNTH 0.04
- Stochastic Oscillator
- RDW 84.94
- DNTH 30.84
About RDW Redwire Corporation
Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's Heritage plus Innovation strategy enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.